Ind-Swift Labs Q1 FY27: Op. EBITDA up 2.85x YoY to ₹33.32 Cr

Ind-Swift Laboratories Ltd announced robust Q1 FY27 results, with operating EBITDA surging 2.85x year-on-year to ₹33.32 crore and EBITDA margin expanding to 17.91%. Profit After Tax (PAT) excluding exceptional items jumped 2.04x YoY to ₹24.68 crore, with PAT margin improving to 13.26%. The company highlighted its transformation into a focused, debt-free formulations manufacturer, with significant contributions expected from new CDMO partnerships and product commercializations. Key milestones include the commercialization of Viatris, Manx, and Arrotex CDMO partnerships, expected to add ₹200-220 crore in FY27. The company also saw growth in its global dossier pipeline and product registrations, and is progressing the upgrade of its Samba manufacturing facility to EU-GMP and PIC/S standards. Ind-Swift projects over 50% revenue growth in FY27 and a medium-term CAGR of 20-25%.